secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-07-12T23:59:59+00:00
Accession:  0001493152-24-027086
Event type: regulatory
Sentiment:  neutral
Materiality: 0.25
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte gets Nasdaq notice of prior noncompliance and regained compliance after director death
--------------------------------------------------------------------------------

- Director Alfred D. Kingsley died April 25, 2024, causing noncompliance with Nasdaq independent board and audit committee rules.
- Effective July 1, 2024, director Andrew Arno was deemed independent and appointed to the audit committee, restoring compliance.
- Nasdaq Staff confirmed compliance on July 8, 2024; no further action required.
- The company had previously disclosed the independence determination in a Form 8-K filed July 5, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224027086/0001493152-24-027086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224027086/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-027086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer